MDAT

MDAT

Systematic (IUPAC) name
5,6,7,8-tetrahydrobenzo[f][1,3]benzodioxol-7-amine
Clinical data
Legal status	Uncontrolled
Routes of administration	Oral
Identifiers
CAS Number	101625-35-8 freebase 33446-21-8 hydrochloride salt
ATC code	none
PubChem	CID: 36483
ChemSpider	33531
Chemical data
Formula	C11H13NO2
Molecular mass	191.223 g/mol
SMILES C3Cc1cc2OCOc2cc1CC3N

6,7-Methylenedioxy-2-aminotetralin (MDAT) is a drug developed in the 1990s by a team at Purdue University led by David E. Nichols. It appears to act as a serotonin releasing agent based on rodent drug discrimination assays comparing it to MDMA, in which it fully substitutes for, and additionally lacks any kind of serotonergic neurotoxicity. Hence, MDAT is considered likely to be a non-neurotoxic, putative entactogen in humans.

See also

• 2-Aminotetralin
• 6-CAT
• 8-OH-DPAT
• MDMAT
• MDAI
• MDMAI
• MMAI